Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib,
and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell
Lymphoma (MCL).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Celgene Celgene Corporation Millennium Pharmaceuticals, Inc.